Table 2.
Quantitative analysis of the investigated peripheral ganglia identified on 18F-DCFPyL PET for both cohorts
| Peripheral ganglia | SUVmax | SULmax | SUVmax/Gluteusmean | SULmax/Gluteusmean | SUVmax/Aortamean | SULmax/Aortamean |
|---|---|---|---|---|---|---|
| Prostate cancer | ||||||
| Cervical | 1.82 (0.36) | 1.36 (0.26) | 4.37 (1.30) | 4.16 (1.21) | 1.36 (0.39) | 1.49 (1.00) |
| Stellate | 1.69 (0.49) | 1.28 (0.37) | 4.23 (1.48) | 3.93 (1.31) | 1.30 (0.45) | 1.45 (1.05) |
| Celiac | 1.69 (0.58) | 1.28 (0.46) | 4.29 (2.11) | 4.11 (1.70) | 1.26 (0.57) | 1.43 (1.43) |
| Lumbar | 1.78 (0.31) | 1.34 (0.22) | 4.55 (1.14) | 4.26 (1.34) | 1.35 (0.36) | 1.47 (0.74) |
| Sacral | 1.85 (0.52) | 1.33 (0.30) | 4.20 (1.97) | 3.85 (1.16) | 1.37 (0.39) | 1.37 (0.39) |
| Renal cell carcinoma | ||||||
| Cervical | 1.81 (0.29) | 1.30 (0.22) | 3.73 (1.33) | 3.67 (1.39) | 1.48 (0.91) | 1.60 (1.13) |
| Stellate | 1.56 (0.36) | 1.17 (0.36) | 3.45 (1.90) | 3.35 (2.00) | 1.06 (0.29) | 1.08 (0.30) |
| Celiac | 2.06 (0.55) | 1.44 (0.42) | 4.30 (1.61) | 3.90 (1.84) | 2.18 (2.14) | 2.09 (2.03) |
| Lumbar | 1.71 (0.32) | 1.21 (0.17) | 3.43 (1.13) | 3.43 (1.21) | 1.43 (0.88) | 1.52 (1.05) |
| Sacral | 2.03 (0.38) | 1.42 (0.38) | 4.30 (2.59) | 4.29 (2.63) | 3.73 (2.26) | 3.64 (2.14) |
Mean and standard deviation are given